<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116479</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2009-109</org_study_id>
    <nct_id>NCT01116479</nct_id>
  </id_info>
  <brief_title>Optimal Transfusion in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)</brief_title>
  <acronym>HaemOPtimal</acronym>
  <official_title>Randomised Feasibility Study of Optimal Transfusion Thresholds in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This an open two-arm interventional randomised feasibility study in anaemic patients treated&#xD;
      with chemotherapy. Randomisation is performed between two transfusion thresholds: Haemoglobin&#xD;
      &lt; 6.0 mmol/l (9.9 g/dL) versus haemoglobin &lt; 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l&#xD;
      (13.4 g/dL) for males.Primary end-point is quality of life&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:&#xD;
&#xD;
      Randomised Feasibility Study of Optimal Transfusion Thresholds in Anaemic Cancer Patients&#xD;
      Treated with Chemotherapy (HaemOPtimal)&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Cancer patients treated with chemotherapy very often become anaemic, which have profound&#xD;
      negative impact of their quality of life. Blood transfusions can ameliorate symptoms caused&#xD;
      by anaemia. Data are lagging with regard to what threshold should be used when offering blood&#xD;
      transfusion.&#xD;
&#xD;
      Aim:&#xD;
&#xD;
      The primary aim is to determine which end-points reflect symptoms caused by anaemia in cancer&#xD;
      patients treated with chemotherapy. The secondary aims are to collect data to estimate sample&#xD;
      size in a future definitive study and to compare symptom relief using to different&#xD;
      transfusion thresholds.&#xD;
&#xD;
      End-points:&#xD;
&#xD;
        -  Numeric Rating Scale measuring fatigue, dizziness, palpitations, headache, and dyspnea.&#xD;
&#xD;
        -  FACT-G,&#xD;
&#xD;
        -  FACT-An (Total anemia scale) including a fatigue subscale&#xD;
&#xD;
        -  Patient-assessed WHO performance status&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Open two-arm interventional randomised feasibility study&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
        -  Blood transfusion.&#xD;
&#xD;
        -  Randomisation between two transfusion thresholds:&#xD;
&#xD;
      Haemoglobin &lt; 6.0 mmol/l (9.9 g/dL) versus Haemoglobin &lt; 7.1 mmol/l (11.7 g/dL) for female&#xD;
      and 8.1 mmol/l (13.4 g/dL) for males.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Cancer patients treated with chemotherapy&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Documented cancer&#xD;
&#xD;
        -  Planned treatment with chemotherapy&#xD;
&#xD;
        -  Age 18 years or older&#xD;
&#xD;
        -  Informed consent&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Heart failure (NYHA 3 and 4)&#xD;
&#xD;
        -  Prior serious complications to blood transfusion&#xD;
&#xD;
        -  Medical conditions that require special considerations for blood transfusion&#xD;
&#xD;
        -  Treatment with erythropoiesis-stimulating agents.&#xD;
&#xD;
      Number of patients:&#xD;
&#xD;
      Transfusion of at least 30 patients in each intervention arm. An estimated number of 90&#xD;
      patients will be randomised in each arm (180 in total) as a third of included patients are&#xD;
      expected to require transfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FACT-G, FACT-An, Numeric Rating Scale on symptoms of anaemia, Performance status</measure>
    <time_frame>Before each cylces of chemotherapy in up to six months, and before transfusion, and daily in seven days after transfusion</time_frame>
    <description>Patient assessed FACT-G (Functional Assessment of Therapy in General), FACT-An (Functional Assessment of Therapy in Anaemia), Numeric Rating Scale on symptoms of anaemia (fatigue, dizziness, dyspnea, palpitations, headache) and performance status before each cycle of chemotherapy, before transfusion and daily in seven days after transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and transfusion complications</measure>
    <time_frame>during or after transfusion</time_frame>
    <description>Frequency of complications to blood transfusion (need for termination of transfusion due to complications, chills, fever, hives, drop in blood pressure, dyspnea, other)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cancer</condition>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Haemoglobin (&lt;6.0 mmol/l)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood transfusion thresholds:Haemoglobin &lt; 6.0 mmol/l (9.9 g/dL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haemoglobin (&lt; normal range)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood transfusion threshold: Haemoglobin &lt; 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood transfusion</intervention_name>
    <description>Blood transfusion with packed erythrocytes</description>
    <arm_group_label>Haemoglobin (&lt; normal range)</arm_group_label>
    <arm_group_label>Haemoglobin (&lt;6.0 mmol/l)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented cancer&#xD;
&#xD;
          -  Planned treatment with chemotherapy&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure (NYHA 3 and 4)&#xD;
&#xD;
          -  Prior serious complications to blood transfusion&#xD;
&#xD;
          -  Medical conditions that require special considerations for blood transfusion&#xD;
&#xD;
          -  Treatment with erythropoiesis-stimulating agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Sorensen, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Oncology, Righospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood bank, Righospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Morten Sorensen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Anaemia, transfusion, cancer, chemotherapy, Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

